AstraZeneca (BSP:A1ZN34) Other Long-Term Liabilities : R$26,050 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is AstraZeneca Other Long-Term Liabilities?

AstraZeneca's other long-term liabilities for the quarter that ended in Mar. 2025 was R$26,050 Mil.

AstraZeneca's quarterly other long-term liabilities increased from Sep. 2024 (R$25,834 Mil) to Dec. 2024 (R$26,881 Mil) but then declined from Dec. 2024 (R$26,881 Mil) to Mar. 2025 (R$26,050 Mil).

AstraZeneca's annual other long-term liabilities declined from Dec. 2022 (R$25,356 Mil) to Dec. 2023 (R$19,854 Mil) but then increased from Dec. 2023 (R$19,854 Mil) to Dec. 2024 (R$26,881 Mil).

AstraZeneca Other Long-Term Liabilities Historical Data

The historical data trend for AstraZeneca's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Other Long-Term Liabilities Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

30,328.01

49,740.50

25,356.26

19,853.99

26,881.01

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															18,898.34	24,065.09	25,833.84	26,881.01	26,049.64

AstraZeneca Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

AstraZeneca Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BSP:A1ZN34) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines